Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.
Events & Presentations
10:00 AM EDT
Morgan Stanley 16th Annual Global Healthcare Conference
8:00 AM EDT
Q2 2018 Incyte Corporation Earnings Conference Call
1:00 PM EDT
2018 Investor & Analyst Event